Economic cost-utility analysis of stage-directed oesophageal cancer treatment
BJS Open
.
2024 Mar 1;8(2):zrad159.
doi: 10.1093/bjsopen/zrad159.
Authors
Geraint L Herbert
1
2
3
4
,
David B T Robinson
1
2
,
Arfon G Powell
5
,
Tarig Abdelrahman
2
,
Usman Khalid
1
2
3
6
,
Wyn G Lewis
1
2
3
4
Affiliations
1
Health Education and Improvement Wales, Tŷ Dysgu, Cefn Coed, Nantgarw, UK.
2
Department of Surgery, University Hospital of Wales, Heath Park Way, Cardiff, UK.
3
School of Medicine, Cardiff University, Cardiff, UK.
4
Department of Surgery, Aneurin Bevan University Health Board, Grange University Hospital, Caerleon Road, Llanfrechfa, Cwmbran, UK.
5
Greater Manchester Oesophagogastric Surgery Unit, Salford Royal Hospital, Stott Lane, Salford, UK.
6
Wales Kidney Research Unit, Division of Infection and Immunity, Cardiff University School of Medicine, Cardiff, UK.
PMID:
38557866
PMCID:
PMC11058869
DOI:
10.1093/bjsopen/zrad159
No abstract available
MeSH terms
Adenocarcinoma* / therapy
Cost-Benefit Analysis
Esophageal Neoplasms* / therapy
Humans